$30.92 $0.53 (1.7%)

04:00 PM EST on 12/06/19

Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 4 out of 5

Current Price $30.92 Mkt Cap $1.6B
Open $30.60 P/E Ratio 0.00
Prev. Close $30.39 Div. (Yield) $0.00 (0.0%)
Daily Range $30.11 - $31.13 Volume 1,141,004
52-Wk Range $19.00 - $31.78 Avg. Daily Vol. 877,274


How do you think NASDAQ:EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

236 Outperform
11 Underperform

All-Star Players

81 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rhallbick (88.19)
Submitted April 15, 2018

Editas Medicine (NASDAQ: EDIT) is a biotech specializing in CRISPR-Cas9 research and development. CRISPR has promise for the treatment of patients with genetically defined diseases by correcting their disease?causing genes.CRISPR is an acronym for… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.



Fools bullish on NASDAQ:EDIT are also bullish on:

Fools bearish on NASDAQ:EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.


Member Avatar SurfingCabarete (29.92) Submitted: 7/9/2019 12:17:57 PM : Outperform Start Price: $23.84 NASDAQ:EDIT Score: +23.61

bet on gene editing


Member Avatar WilliamEbonics (62.04) Submitted: 5/20/2019 5:28:14 PM : Underperform Start Price: $22.17 NASDAQ:EDIT Score: -29.31

The Stock continues a downward drift, while money also continues to exit the stock over an extended period of time.


Member Avatar MarkFitzFool (46.43) Submitted: 5/11/2019 3:08:22 PM : Outperform Start Price: $24.45 NASDAQ:EDIT Score: +14.98

It's been a bumpy ride for Editas over the past few years, but such is the nature of being a developmental stage biotech company. What sets Editas apart is their leadership. Feng Zhang, one of the developers of both CRISPR and optogenetics, is a co-founder, as is George Church, one of the most famous scientists in the world and a pioneer of both synthetic biology and personalized genomics. Editas is early-stage, and inherently risky, but I'm extremely confident that they will prevail. They have a robust developmental and preclinical pipeline with therapies for Beta-Thalassemia, Sickle Cell, DMD, Cystic Fibrosis, genetic diseases of the eye and liver, CAR-T for cancer therapy, etc. Will they be the first to market with one of their cutting-edge non-CAR-T gene-editing therapies? Likely not (I think bluebird bio will beat them), but they have many promising shots on goal that position them to be a leader in the space. Furthermore, The Broad Institute holds several CRISPR patents, and both Zhang and Church are members of said institute. I foresee Editas being one the future's top companies for personalized genetic therapies.


Find the members with the highest scoring picks in EDIT.

Score Leader


PAGEBOY73 (99.26) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Member Name Member
Call Time
Score Commentary
SeriousK 28.85 3/9/2016 Underperform 5Y $42.70 -27.59% +57.93% +85.52 0 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +100.35% +29.28% +71.07 1 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +113.54% +47.57% +65.97 0 Comment
FunesDMemorious 97.89 10/26/2016 Outperform 5Y $14.55 +112.51% +47.67% +64.84 0 Comment
portefeuille 98.38 2/10/2016 Outperform 5Y $13.26 +133.18% +68.85% +64.33 0 Comment
CMFMLove 43.16 6/13/2017 Outperform 5Y $16.00 +93.25% +29.05% +64.20 1 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +92.29% +28.99% +63.30 0 Comment
portefeuille2 99.12 9/22/2016 Outperform 5Y $14.87 +107.94% +45.11% +62.82 0 Comment
TimeToBuy 88.29 3/10/2016 Underperform 5Y $32.50 -4.86% +57.46% +62.32 0 Comment
forcel0 90.82 11/23/2016 Outperform 5Y $15.60 +98.21% +43.08% +55.12 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.